Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443326 | 0.96 | EPHX2 (0.50) | EPHX2HTR1AHTR2AWNT3ADRD2 | |
| SCHEMBL12812492 | 0.93 | EPHX2 (0.49) | EPHX2HTR1AHTR2AWNT3ADRD2 | |
| SCHEMBL12812495 | 0.91 | HTR1A (0.52) | EPHX2HTR1AHTR2AWNT3ADRD2 | |
| SCHEMBL1442518 | 0.91 | WNT3A (0.48) | EPHX2HTR1AWNT3ADRD2MCHR1 | |
| SCHEMBL1442383 | 0.89 | WNT3A (0.49) | EPHX2HTR1AWNT3ADRD2MCHR1 | |
| SCHEMBL1442581 | 0.89 | HTR1A (0.59) | HTR1AWNT3ADRD2MEN1KMT2A | |
| SCHEMBL12812502 | 0.89 | MCHR1 (0.50) | HTR1AWNT3ADRD2MCHR1MEN1 | |
| SCHEMBL1442853 | 0.88 | WNT3A (0.47) | EPHX2HTR1AWNT3ADRD2MCHR1 | |
| SCHEMBL1442909 | 0.87 | EPHX2 (0.54) | EPHX2HTR1AWNT3ADRD2MEN1 | |
| SCHEMBL10180949 | 0.87 | NPC1 (0.57) | HTR1AWNT3ADRD2MCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | claimed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | claimed |
| EP-2473498-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-11 | — | — | EP | claimed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | claimed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | EPHX2 3175/4885HTR1A 2805/4885HTR2A 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.